Kura Oncology (NASDAQ:KURA) Rating Lowered to Hold at Zacks Investment Research
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other analysts have also recently commented on KURA. Wedbush initiated coverage on Pinterest in a report on Monday, June 17th. They issued an outperform rating and a $33.00 price target for the company. HC Wainwright set a $31.00 price target on Kura Oncology and gave the company a buy rating in a report on Wednesday, May 8th. Oppenheimer set a $13.00 price target on Alpine Immune Sciences and gave the company a buy rating in a report on Tuesday, March 19th. Leerink Swann set a $27.00 price target on Kura Oncology and gave the company a buy rating in a report on Saturday, June 15th. Finally, Cowen reissued a buy rating on shares of Kura Oncology in a report on Monday, June 17th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Kura Oncology has a consensus rating of Buy and a consensus target price of $28.00.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. As a group, research analysts forecast that Kura Oncology will post -1.71 EPS for the current fiscal year.
In related news, insider Antonio Gualberto sold 18,000 shares of Kura Oncology stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total transaction of $379,980.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 15.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its holdings in Kura Oncology by 21.7% during the fourth quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock worth $73,000 after purchasing an additional 923 shares during the last quarter. CWM LLC acquired a new position in Kura Oncology during the first quarter worth $25,000. DekaBank Deutsche Girozentrale raised its holdings in Kura Oncology by 22.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 12,000 shares of the company’s stock worth $235,000 after purchasing an additional 2,200 shares during the last quarter. Legacy Advisors LLC acquired a new position in Kura Oncology during the first quarter worth $65,000. Finally, Alps Advisors Inc. raised its holdings in Kura Oncology by 4.5% during the first quarter. Alps Advisors Inc. now owns 91,873 shares of the company’s stock worth $1,524,000 after purchasing an additional 3,974 shares during the last quarter. 83.93% of the stock is owned by hedge funds and other institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.